J.W. Cole Advisors Inc. Buys 8,130 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

J.W. Cole Advisors Inc. grew its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 59.8% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 21,727 shares of the biopharmaceutical company's stock after purchasing an additional 8,130 shares during the quarter. J.W. Cole Advisors Inc.'s holdings in Gilead Sciences were worth $2,435,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Redwood Financial Network Corp grew its position in shares of Gilead Sciences by 4.0% in the 4th quarter. Redwood Financial Network Corp now owns 2,530 shares of the biopharmaceutical company's stock worth $234,000 after buying an additional 98 shares during the period. Argentarii LLC grew its position in shares of Gilead Sciences by 3.0% in the 1st quarter. Argentarii LLC now owns 3,392 shares of the biopharmaceutical company's stock worth $380,000 after buying an additional 99 shares during the period. Nicolet Advisory Services LLC grew its position in shares of Gilead Sciences by 2.9% in the 4th quarter. Nicolet Advisory Services LLC now owns 3,580 shares of the biopharmaceutical company's stock worth $322,000 after buying an additional 100 shares during the period. Peak Financial Advisors LLC grew its position in shares of Gilead Sciences by 1.7% in the 1st quarter. Peak Financial Advisors LLC now owns 6,040 shares of the biopharmaceutical company's stock worth $677,000 after buying an additional 100 shares during the period. Finally, Perkins Coie Trust Co grew its position in shares of Gilead Sciences by 2.6% in the 1st quarter. Perkins Coie Trust Co now owns 3,880 shares of the biopharmaceutical company's stock worth $435,000 after buying an additional 100 shares during the period. 83.67% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently commented on GILD. Cantor Fitzgerald began coverage on shares of Gilead Sciences in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $125.00 price objective on the stock. Morgan Stanley increased their price objective on shares of Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a research report on Friday, April 25th. Needham & Company LLC reissued a "hold" rating on shares of Gilead Sciences in a research report on Wednesday, May 21st. JPMorgan Chase & Co. upped their target price on shares of Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a research note on Thursday, March 27th. Finally, Oppenheimer lowered their target price on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a research note on Friday, April 25th. Nine research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $111.38.

Gilead Sciences Stock Up 0.1%

Shares of GILD opened at $108.28 on Tuesday. The firm has a market capitalization of $134.69 billion, a P/E ratio of 22.80, a P/E/G ratio of 0.70 and a beta of 0.29. Gilead Sciences, Inc. has a 12-month low of $70.78 and a 12-month high of $119.96. The company has a current ratio of 1.37, a quick ratio of 1.23 and a debt-to-equity ratio of 1.16. The firm has a fifty day moving average price of $108.81 and a 200-day moving average price of $105.35.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.77 by $0.04. The firm had revenue of $6.67 billion during the quarter, compared to analyst estimates of $6.77 billion. Gilead Sciences had a net margin of 20.76% and a return on equity of 51.93%. The business's revenue was down .3% on a year-over-year basis. During the same period in the previous year, the firm earned ($1.32) earnings per share. Equities research analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, Director Jeffrey Bluestone sold 5,000 shares of the business's stock in a transaction dated Monday, July 14th. The shares were sold at an average price of $109.74, for a total value of $548,700.00. Following the completion of the transaction, the director directly owned 8,920 shares in the company, valued at approximately $978,880.80. The trade was a 35.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Johanna Mercier sold 3,000 shares of the business's stock in a transaction dated Tuesday, July 15th. The stock was sold at an average price of $111.03, for a total transaction of $333,090.00. Following the completion of the transaction, the insider owned 117,168 shares of the company's stock, valued at $13,009,163.04. This represents a 2.50% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 72,000 shares of company stock valued at $7,844,775. Insiders own 0.27% of the company's stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.